STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump announced a 100% tariff on imported generic medicines starting August 2028, rising to 200% in August 2029, in a social media post — well after his second term ends
- The administration had previously said generics would be exempt from tariffs, and Trump has repeatedly threatened steep pharmaceutical tariffs without following through
- Doctors and supply chain experts sharply criticized the plan, warning it threatens to raise costs, spur rationing, and cause shortages of crucial drugs
- Indian drugmakers, the largest source of generic therapies for the U.S. and known as the 'pharmacy of the world,' are unsettled by the plan in their biggest export market
- In 2024, Indian medicines accounted for more than half of all U.S. prescriptions for birth control, antidepressants, and hypertension treatments, and India hosts the highest number of FDA-approved manufacturing plants outside the U.S.
Why it matters: Indian pharma supplies more than half of U.S. prescriptions for birth control, antidepressants, and hypertension drugs — and doctors warn the tariffs could raise patient costs, force rationing, and trigger shortages of essential generic medications Americans depend on daily.
